SIREN : 515050284
KORBER PHARMA is a French company founded 16 years ago, specialized in the sector Programmation informatique. Based in LABEGE (31670), this company of category PME shows in 2024 a revenue of 9.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 300 445 € | 7 607 846 € | 6 590 918 € | N/C | N/C | N/C | 1 204 652 € | 545 000 € | 555 000 € |
| Net income | 1 587 120 € | 509 823 € | 333 474 € | 230 232 € | 58 101 € | 8 117 € | 34 618 € | 24 445 € | 29 487 € |
| EBITDA | 1 940 468 € | 1 636 999 € | 435 676 € | N/C | N/C | N/C | 7 024 € | -94 541 € | 47 838 € |
| Net margin | 17.1% | 6.7% | 5.1% | N/C | N/C | N/C | 2.9% | 4.5% | 5.3% |
In 2024, KORBER PHARMA achieves revenue of 9.3 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +42.2%. Vs 2023, growth of +22% (7.6 M€ -> 9.3 M€). After deducting consumption (597 k€), gross margin stands at 8.7 M€, i.e. a rate of 94%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.9 M€, representing 20.9% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.6 M€, i.e. 17.1% of revenue. This profit can be retained or distributed to shareholders.
9 300 445 €
8 703 095 €
1 940 468 €
1 978 062 €
1 587 120 €
20.9%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 21%. The balance between equity and debt is satisfactory. Cash flow represents 16.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.0%
20.801%
16.551%
0.0
49.4%
In 2024, the debt ratio of KORBER PHARMA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of KORBER PHARMA (20.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of KORBER PHARMA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 190.53. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
190.534
0.0
In 2024, the liquidity ratio of KORBER PHARMA (190.53) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of KORBER PHARMA (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 163 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 41 days. The gap of 122 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Inventory turnover is 44 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 111 days of revenue, i.e. 2.9 M€ to permanently finance. Over 2016-2024, WCR increased by +1233%, requiring additional financing.
2 871 140 €
163 j
41 j
44 j
111 j
Based on 120 transactions of similar company sales (all years), the value of KORBER PHARMA is estimated at 3 598 602 € (range 1 661 082€ - 9 675 427€). With an EBITDA of 1 940 468€, the sector multiple of 2.2x is applied. The price/revenue ratio is 0.27x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 120 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare KORBER PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Programmation informatique
The revenue of KORBER PHARMA in 2024 is 9.3 M€.
Yes, KORBER PHARMA generated a net profit of 1.6 M€ in 2024.
The headquarters of KORBER PHARMA is located in LABEGE (31670), in the department Haute-Garonne.
The tax return of KORBER PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
KORBER PHARMA operates in the sector Programmation informatique (NAF code 62.01Z). See the 'Sector positioning' section above to compare the company with its competitors.